HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VITAL Ancillary Study Results Cast More Doubt On Cardio Benefit From Omega-3, Vitamin D

Executive Summary

AF events occurred in 469 (3.7%) of subjects receiving EPA and DHA supplements compared to 431 (3.4%) of participants receiving placebos. In vitamin D3 and placebo comparison, AF events occurred in 469 (3.7%) versus 431 (3.4%).

You may also be interested in...



STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.

Vitamin D Benefits Don’t Extend To Preventing Depression In Older Adults – Study

Vitamin D3 intake didn’t prevent depression among consumers 50 and up, according to results of a five-year study published in the Journal of the American Medical Association. The research was among first studies “statistically powered” to answer long-standing question on vitamin’s benefit on mood.

FDA Holds Line On Omega-3 Claims, But Gives Enforcement Discretion For More

Agency says "some credible evidence" suggests intake of  EPA and DHA "may reduce the risk of hypertension by lowering blood pressure, this evidence is inconclusive and highly inconsistent" and does not support actual approval of a qualified health claim.

Topics

UsernamePublicRestriction

Register

RS151188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel